Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (20)

2021

  1. Idiotype vaccines produced with a non-cytopathic alphavirus self-amplifying RNA vector induce antitumor responses in a murine model of B-cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

    British Journal of Haematology, Vol. 189, Núm. 6, pp. 1064-1073

2019

  1. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach

    British Journal of Clinical Pharmacology, Vol. 85, Núm. 8, pp. 1670-1683

2017

  1. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Journal of Translational Medicine, Vol. 15, Núm. 1

  2. Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity

    Immunologic Research, Vol. 64, Núm. 2, pp. 548-557

  2. Tumor-Produced Interleukin-8 Attracts human myeloid-derived suppressor cells and elicits extrusion of Neutrophil Extracellular Traps (NETs)

    Clinical Cancer Research, Vol. 22, Núm. 15, pp. 3924-3936

2008

  1. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis

    European Journal of Immunology, Vol. 38, Núm. 2, pp. 576-586

2007

  1. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor

    Journal of Biological Chemistry, Vol. 282, Núm. 10, pp. 7405-7415

  2. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions

    Journal of Investigative Dermatology, Vol. 127, Núm. 7, pp. 1673-1680

  3. La terapia celular antitumoral

    Gastroenterologia y Hepatologia Continuada

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301

2004

  1. Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis

    Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761

  2. Imatinib mesylate in cutaneous melanoma [7]

    Journal of Investigative Dermatology

  3. Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: Implications for anti-idiotype vaccine development

    Critical Reviews in Oncology/Hematology, Vol. 52, Núm. 1, pp. 1-7

2003

  1. Estrategias terapéuticas con vacunas idiotípicas en el tratamiento del linfoma folicular

    Hematologia - Citocinas, Inmunoterapia y Terapia Celular, Vol. 6, Núm. 3, pp. 175-182

  2. Feasibility of idiotype vaccination in relapsed B-cell malignancies

    Haematologica, Vol. 88, Núm. 12, pp. 1438-1440

2001

  1. Factors determining the actual received dose intensity in a program of multicyclic dose-intensive alternating chemotherapy with sequential stem cell support

    Acta Haematologica

2000

  1. Clinico-pathologic, immunohistochemical, and TUNEL study in early cardiac allograft failure

    Cardiovascular Pathology, Vol. 9, Núm. 3, pp. 153-159

1998

  1. Progressive decrease of CD8(high+) CD28+ CD57- cells with ageing

    Clinical and Experimental Immunology, Vol. 112, Núm. 1, pp. 48-51